Xabitor 40 Tablet contains Febuxostat 40 mg, a xanthine oxidase inhibitor indicated for the management of hyperuricemia in patients with gout. Febuxostat works by selectively inhibiting xanthine oxidase, an enzyme responsible for the conversion of hypoxanthine to xanthine and xanthine to uric acid, thereby reducing serum uric acid levels. This reduction helps prevent gout attacks and the formation of urate crystals in joints and tissues. Xabitor 40 is prescribed for patients who have not responded adequately to conventional urate-lowering therapies or who are intolerant to allopurinol. The recommended dosage is typically 40 mg once daily, which may be adjusted based on serum uric acid levels and clinical response. It is important to monitor liver function tests periodically during treatment due to potential hepatotoxicity. Common adverse effects include nausea, rash, and joint pain, while serious side effects may involve cardiovascular events; therefore, caution is advised in patients with a history of cardiovascular disease. Xabitor 40 should be used under medical supervision, with attention to contraindications such as hypersensitivity to Febuxostat or severe hepatic impairment. Patient adherence and regular monitoring are essential for optimal therapeutic outcomes.